Pharmacologists research is essential for developing new medications, understanding drug mechanisms, and ensuring the safety and efficacy of treatments. In drug development, pharmacologists investigate how compounds affect the body at the molecular, cellular, and systemic levels. They study pharmacokinetics (how drugs are absorbed, distributed, metabolized, and excreted) and pharmacodynamics (how drugs produce their effects). Their work helps design safer and more effective medications for conditions such as cancer, cardiovascular disease, and neurological disorders. Pharmacologists also play a crucial role in toxicology, determining safe dosage levels and identifying potential side effects of drugs. They work closely with regulatory agencies to ensure new drugs meet safety standards before being approved for public use. Beyond medicine, pharmacologists contribute to fields like biotechnology, agriculture, and environmental science by studying the effects of chemicals on living organisms. Their research continues to drive innovations in personalized medicine, targeted therapies, and drug delivery systems, improving healthcare outcomes worldwide.
Pharmacologists work in pharmaceutical companies, research institutions, hospitals, and regulatory agencies. They play a key role in preclinical and clinical trials, ensuring that new drugs undergo rigorous testing before approval by regulatory bodies such as the FDA or EMA. With advancements in personalized medicine, pharmacologists are now studying how genetic differences affect drug responses, leading to more tailored and effective treatments.
Title : Results from a cross-sectional observational study examining irritable bowel syndrome patients six months after finishing their participation in the ViIBS trial
Jacek Piatek, Calisia University, Poland
Title : Gut microbiome as a driver of healthy ageing
Thi Thu Hao Van, RMIT University, Australia
Title : Treating irritable bowel syndrome patients with a balanced multi-strain synbiotic–results from a multi-center, randomized, double-blind, placebo-controlled clinical trial (the ViIBS trial)
Henning Sommermeyer, Calisia University, Poland
Title : Molecular mechanisms underlying the anti-atherogenic actions of probiotics
Dipak P Ramji, Cardiff University, United Kingdom
Title : Global regulatory trends on the use of probiotics and prebiotics in foods and food supplements
David Pineda Ereno, DPE International Consulting, Belgium
Title : Biochemical profile and nutripotential glimpses of Terminalia arjuna bark extract
Suriyavathana Muthukrishnan, Periyar University, India